In vitro evaluation of difloxacin (A-56619), A-56620, and other 4-quinolones against isolates from cancer patients.
The in vitro activity of two new quinolones, difloxacin and A-56620, was compared with that of other quinolones against isolates obtained from bacteremic cancer patients. Both agents had a broad antimicrobial spectrum which included both gram-positive and gram-negative organisms. A-56620 had lower MIC values against most organisms tested than difloxacin, and its activity was comparable to that of ciprofloxacin.
Division of Medicine, University of Texas M.D. Anderson Hospital and Tumor Institute, Houston.
K V
KV
Rolston
D H
DH
Ho
B
B
LeBlanc
G P
GP
Bodey
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002939:Ciprofloxacin / Q000031:analogs & derivatives* / Q000494:pharmacology; D004353:Drug Evaluation, Preclinical; D024841:Fluoroquinolones; D006090:Gram-Negative Bacteria / Q000187:drug effects*; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D006801:Humans; D008826:Microbial Sensitivity Tests; D009369:Neoplasms / Q000150:complications; D011809:Quinones / Q000494:pharmacology; D018805:Sepsis / Q000150:complications
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D011809:Quinones; D002939:Ciprofloxacin; C047225:difloxacin; C047224:sarafloxacin